Abstract: A vital signs monitoring ring with integrated display includes a ring housing, the ring housing comprising at least two windows and a printed circuit board assembly (PCBA) layer configured to be attached to the ring housing. The PCBA layer includes a display section, a sensor section, a transmission mode oximetry measurement section configured to be in alignment with the at least two windows, a power supply, and a switch configured to power on the vital signs monitoring ring with integrated display via the power supply. The display section is configured to display physiological and action parameters associated with a user by sensing the physiological and action signals from a digit of user wearing the vital signs monitoring ring with integrated display using at least the sensor section and the transmission mode oximetry measurement section.

Abstract: A vital signs monitoring patch with integrated display (VSM) includes a user access layer for accessing a display section and a first printed silver-silver chloride (Ag—AgCl) electrode. A polyethylene foam layer including battery and plunger cut-outs. A printed circuit board assembly (PCBA) layer including vitals sign monitoring sensors and the battery and connected to the first and second printed Ag—AgCl electrodes. The polyethylene foam layer bonded to the user access layer and the PCBA layer. A sensor layer including reflection mode oximetry components and the second printed Ag—AgCl electrode. A hydrogel conductive adhesive to interact between a user skin and the second printed Ag—AgCl electrode. A medical tape layer bonded to the user skin and the sensor layer. A plunger connected to the PCBA layer and configured to power on the VSM, where user access of the first printed Ag—AgCl electrode completes a circuit with the second printed Ag—AgCl electrode.

Abstract: Described herein are devices for approximating targeted tissue by intertwining two or more sutures together. The sutures are attached to the targeted tissue and routed to a twister device. The twister device secures end portions of the sutures and twists them to intertwine the sutures. Controlling the number of twists provides control over the forces applied to the targeted tissue. In conjunction with visualization feedback, real-time adjustments can be made to achieved targeted results, such as elimination of mitral regurgitation when the disclosed methods and apparatus are applied to mitral valve repair.

Abstract: A vital signs monitoring ring with integrated display includes a ring housing, the ring housing comprising at least two windows and a printed circuit board assembly (PCBA) layer configured to be attached to the ring housing. The PCBA layer includes a display section, a sensor section, a transmission mode oximetry measurement section configured to be in alignment with the at least two windows, a power supply, and a switch configured to power on the vital signs monitoring ring with integrated display via the power supply. The display section is configured to display physiological and action parameters associated with a user by sensing the physiological and action signals from a digit of user wearing the vital signs monitoring ring with integrated display using at least the sensor section and the transmission mode oximetry measurement section.

Abstract: Disclosed herein are wearable bands for biomarker tracking and methods for making the wearable bands. The biomarker tracking wearable band having a printed circuit board assembly (PCBA), the PCBA including an electrocardiography (ECG) sensor utilizing printed Silver-Silver Chloride (Ag-AgCl) electrodes and an optical photoplethysmography (PPG) sensor utilizing more than two light emitting diodes (LEDs), and a directly over molded band encasing the PCBA.

Abstract: A request is received from a computing device for substitute data, with access to the substitute data being contingent upon successful multi-factor authentication of the first service. Signature data based on the request is generated using a first key of public-private key pair. Credential proof and the signature is provided to a second service, which verifies the credential proof as a first factor of the multi-factor authentication and verifies, using a second key, the signature as a second factor of the multi-factor authentication. The substitute data is obtained as a result of authentication by the second service. The computing device is caused, by providing the substitute data to the computing device, to input the substitute data into the interface in place of data associated with the first entity.

Abstract: Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:

Abstract: A vital signs monitoring patch with integrated display (VSM) includes a user access layer for accessing a display section and a first printed silver-silver chloride (Ag—AgCl) electrode. A polyethylene foam layer including battery and plunger cut-outs. A printed circuit board assembly (PCBA) layer including vitals sign monitoring sensors and the battery and connected to the first and second printed Ag—AgCl electrodes. The polyethylene foam layer bonded to the user access layer and the PCBA layer. A sensor layer including reflection mode oximetry components and the second printed Ag—AgCl electrode. A hydrogel conductive adhesive to interact between a user skin and the second printed Ag—AgCl electrode. A medical tape layer bonded to the user skin and the sensor layer. A plunger connected to the PCBA layer and configured to power on the VSM, where user access of the first printed Ag—AgCl electrode completes a circuit with the second printed Ag—AgCl electrode.

Abstract: A printing system comprises one or more printheads arranged to eject ink to a deposition region. Print media are held by vacuum suction against a movable support surface, which transports the print media though the deposition region. The vacuum suction is communicated from a vacuum source to the movable support surface via a vacuum plenum. An airflow control system comprises one or more dampers arranged in the vacuum plenum to control airflow between the vacuum source and the movable support surface. The dampers have an adjustable impedance to airflow through the damper. The airflow control system is configured to adjust the impedance of the damper based on a detected condition of the printing system. A detected condition of the printing system may include, for example, a sensed pressure in the vacuum plenum.

Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.

Abstract: 2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where R1 is hydrogen, and their prodrugs, where R1 is a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.

Abstract: Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl-5-fluoro-4-(3-iso-propyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine (Compound 1) and various salts thereof, preparation methods of these crystalline and amorphous forms, pharmaceutical compositions containing these crystalline or amorphous forms, and use of these crystalline and amorphous forms, or pharmaceutical compositions thereof, for treatment of diseases or disorders associated with cyclin-dependent kinase (CDK), especially CDK4 and CDK6, activities, such as various cancers, are disclosed.

Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGER), such as various cancers, are disclosed.

Abstract: Technology for a computer system that uses unsupervised machine learning (ML) for determining employment training opportunities that individuals can take to make the individuals better suited to fill skill gaps that exist in an enterprise (for example, a company that manufactures commercial products or provides commercial services). Some embodiments include remediation techniques. Some embodiments include a solutions-oriented toolset.

Abstract: Methods are disclosed for treating brain cancers or brain metastases from other cancers, or prevention of brain metastases, associated with CDK4 and/or CDK6 activities, where the methods comprise administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I). Use of a compound of formula (I) for the manufacture of a medicament for treatment of brain cancer or brain metastases from other cancers, or prevention of brain metastases, associated with CDK4 and/or CDK6 activity is also disclosed.

Abstract: The present disclosure provides [1,2,4]triazolo[4,3-b][1,2,4]triazine, [1,2,4] triazolo[4,3-b]pyridazine, and [1,2,3]triazolo[4,5-b]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents.

Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.

Abstract: In an approach to generating and managing personalized private roaming service set identifiers and networks, one or more computer processors generate one or more private networks based on one or more policies associated with a user and capabilities of one or more network providers in a communication proximity to the user. The one or more computer processors create one or more configuration files required to implement the one or more generated private networks on the one or more network providers. The one or more computer processors implement the one or more generated private networks by applying the one or more created configuration files to the one or more network providers.

Abstract: A method, system, and computer program product for contextual generation of an ephemeral network are provided. The method detects an initiating event for network generation associated with a user of a first computing device. The method determines a duration of the initiating event. A set of network members is determined based on the initiating event and the duration. The method establishes an ephemeral network, connecting at least a portion of computing devices associated with the set of network members. The ephemeral network is terminated in response to detecting a completion event. In response to terminating the ephemeral network, member information for the set of network members is removed from the portion of the computing devices.

Abstract: A request is received from a computing device for substitute data, with access to the substitute data being contingent upon successful multi-factor authentication of the first service. Signature data based on the request is generated using a first key of public-private key pair. Credential proof and the signature is provided to a second service, which verifies the credential proof as a first factor of the multi-factor authentication and verifies, using a second key, the signature as a second factor of the multi-factor authentication. The substitute data is obtained as a result of authentication by the second service. The computing device is caused, by providing the substitute data to the computing device, to input the substitute data into the interface in place of data associated with the first entity.